Form 4: Actuate Therapeutics Director, Amy L Ronneberg, Acquires 30,000 Stock Options

Amy L Ronneberg, a director of Actuate Therapeutics, acquired 30,000 non-qualified stock options on August 12, 2024, which vest over three years.

Summary

• On August 12, 2024, Amy L Ronneberg, a director of Actuate Therapeutics, acquired 30,000 non-qualified stock options.
• The options were granted upon the effectiveness of the registration statement for the issuer's initial public offering.
• The exercise price of the options is $8.
• The options vest in three equal installments on the first, second, and third anniversary of the grant date, contingent upon continued service.
• The expiration date for these options is August 12, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns the interests of the director with those of the shareholders. There are no negative indicators in the filing.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, especially after an initial public offering.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of three years is also typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies in the biotech space, such as Amgen or Gilead, also utilize stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• Shareholders may view the option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The director benefits from the potential future value of the stock options.

Key Dates